Point Biopharma Global (NASDAQ: PNT)
Some price data may be temporarily unavailable.
Point Biopharma Global Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Point Biopharma Global Company Info
POINT Biopharma Global, Inc. is a radiopharmaceutical company. It engages in the business of building a platform for the clinical development and commercialization of radioligands that fight cancer. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.
News & Analysis
Why POINT BioPharma Global Stock Skyrocketed 86% This Week
POINT Biopharma is being acquired by Lilly. Here's what investors need to know.
Why Shares of Point Biopharma Global Are Soaring Tuesday
The company entered into a buyout agreement with Eli Lilly.
Why Shares of Point Biopharma Global Rose Monday
The company made a deal to help speed its clinical trials along.
Why Point Biopharma Global Stock Got Crushed Today
The market didn't react well to news of the biotech's latest financing effort.
Why Point Biopharma Global Stock Is Getting Crushed Today
Short-sellers appear to be pouncing on an upcoming scientific presentation.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.